ABSTRACT Background. Recently, there has been an increase in the availability of targeted molecular therapies for cancer treatment. The application of these approaches to esophageal cancer, however, has been hampered by the relative lack of appropriate models for preclinical testing. Patientderived tumor xenograft (PDTX) models are gaining popularity for studying many cancers. Unfortunately, it has proven difficult to generate xenografts from esophageal cancer using these models. The purpose of this study was to improve the engraftment efficiency of esophageal PDTXs. Methods. Fresh pieces of esophageal tumors obtained from endoscopic biopsies or resected specimens were collected from 23 patients. The tumors were then coated in Matrigel and transplanted in immunocompromised mice subcutaneously (n = 6) and/or using a novel implantation technique whereby the tumor is placed in a dorsal intramuscular pocket (n = 18). They are then monitored for engraftment. Results. With the novel intramuscular technique, successful engraftment was achieved for all 18 patient tumors. Among these PDTXs, 13 recapitulated the original patient tumors with respect to degree of differentiation, molecular and genetic profiles, and chemotherapeutic response. Lymphomatous transformation was observed in the other five PDTXs. Successful engraftment was achieved for only one of six patient tumors using the classic subcutaneous approach. Discussion. We achieved a much higher engraftment rate of PDTXs using our novel intramuscular transplant technique than has been reported in other published studies. It is hoped that this advancement will help expedite the development and testing of new therapies for esophageal cancer.
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Esophageal cancer is currently the eighth most common cancer worldwide and has an extremely high case fatality rate. 1 Approximately 83 % of all cases occur in developing countries, where squamous cell carcinoma (SCC) is the main subtype. 2 In the developed world, esophageal adenocarcinoma poses the greater problem, as its incidence has risen more than sixfold over the last four decades. 3 Currently, in the United States, only 17.5 % of all patients who present with esophageal cancer survive more than 5 years. 4 Alternative treatment strategies are needed to improve disease outcomes. Progress is being hampered by a lack of suitable preclinical models with which to study the disease and test new therapies.
One model that has shown great promise in the field of cancer research is the patient-derived tumor xenograft (PDTX), in which the patient's tumor tissue is grown and expanded in immunocompromised mice. As these models recapitulate the original patient tumors with respect to histology, molecular and genetic profiles, and therapeutic response, they are being increasingly used as preclinical models for drug target validation and biomarker identification. 5 PDTXs also have the capacity to provide a perpetual tissue bank, making them a valuable resource, particularly for esophageal cancer, where the collection of treatment-naive tissue is often limited to small endoscopic biopsies obtained prior to neoadjuvant therapy. 6 Unfortunately, there has been limited success in generating esophageal PDTXs, with success rates ranging between 30.0 and 38.5 %. [7] [8] [9] [10] [11] [12] [13] Given the importance of the PDTX model to cancer research, refinements that lead to improvements in engraftment efficiencies are of great benefit.
14 One variable with the potential to improve engraftment efficiency is the transplantation site. Common sites for heterotopic transplantation include subcutaneous (SC) and renal subcapsular spaces. 5 We hypothesized that an intramuscular (IM) transplantation site might provide improved engraftment of PDTXs because of the well-vascularized transplant bed it provides.
MATERIALS AND METHODS

Mice
Scid, NOD scid, NOD-scid interleukin-2 (IL2) receptor gamma chain knockout (NSG), and athymic nude mice were obtained from either the Animal Resource Centre (Canning Vale, Western Australia), or the Walter & Eliza Hall Institute (Melbourne, Victoria), or they were bred internally at the Peter MacCallum Cancer Centre (Melbourne, Victoria). All mice were maintained and housed in the animal facility of the Peter MacCallum Cancer Centre. After obtaining informed consent, fresh samples of either treatment-naive or posttreatment esophageal tumors were collected from patients' endoscopic biopsies or surgical resection specimens. They were placed in chilled phosphate-buffered saline (PBS) supplemented with penicillin 200 U/ml and streptomycin 200 lg/ml (PBS ?? ) and kept on ice. Samples were divided into approximately 2 mm 3 pieces, with any necrotic areas being discarded. Representative fragments were also snap frozen for DNA/ RNA analysis or fixed in 10 % buffered formalin for histological evaluation. The remaining tumor pieces were placed in Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) and kept on ice until implantation. All specimens were implanted within 90 min of collection.
Implantation and Monitoring
Mice were anesthetized via an intraperitoneal injection of 100 ll of anesthetic solution (ketamine 10 mg/ml and xylazine 2 mg/ml) per 10 g of body weight. The dorsum of the mouse was shaved and prepared with a 2 % (v/v) chlorhexidine gluconate/70 % (v/v) isopropyl alcohol solution. Under aseptic conditions, a 15-mm midline incision was made immediately caudal to the dorsal hump. Using blunt dissection, a skin flap was raised and the skin retracted laterally. For IM implantation, a superficial stay suture was placed in the dorsal musculature immediately caudal to the lowest rib using a 4/0 braided absorbable suture. After tenting the muscle fibers, an IM pocket was created using a combination of sharp and blunt dissection until it was just large enough to accommodate the tumor piece. The tumor piece coated in Matrigel was then placed in the IM pocket prior to suture closing (Fig. S1 ). For SC implantation, a tumor piece, similarly coated in Matrigel, was implanted under the raised skin flap. One or two separate transplantation sites were used per mouse. The skin was closed using 3/0 braided absorbable suture. Mice were closely monitored for tumor formation and culled according to guidelines once tumors reached the ethical limit of 1500 mm 3 as calculated by the formula (length 9 width 2 )/2 or at any sign of discomfort and/or stress.
Harvesting and Processing of PDTXs
PDTXs were carefully resected to ensure that the muscle layer was dissected free. After débridement of any necrotic areas, the PDTX was divided into 2 mm 3 pieces and processed as per the original tissue. For cryopreservation, pieces were washed with PBS ?? and then aliquoted into cryovials (up to two per cryovial) containing 1 ml of fetal calf serum containing 10 % (v/v) dimethylsulfoxide and frozen to -80°C at approximately -1°C/min.
Histology and Immunohistochemistry
Sections of formalin-fixed paraffin-embedded tissue from all of the original patient-derived tissues and the PDTXs were stained with hematoxylin and eosin (H&E). To confirm that the PDTXs were of human origin, immunohistochemistry was performed using an antibody against the human mitochondrial antigen, MAB1273 (1:500) (Merck Millipore, Billerica, MA, USA). CK7 (1:50) (POV-TL 12/30; DakoCytomation, Glostrup, Denmark) and CK19 (1:100) (RCK108; DakoCytomation) antibodies were used to confirm that adenocarcinomas were from the esophagus or the gastroesophageal junction. 15 
DNA Extraction and Sequencing
DNA from both the original patient sample and the PDTXs was extracted from freshly frozen pieces of tissue using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) as per the recommended protocol. Targeted sequencing across a panel of 48 known oncogenes was then performed using the Illumina TruSeq Amplicon Cancer Panel as previously described. 16 
Therapeutic Response
For assessment of the chemotherapeutic response, a single PDTX was divided and implanted into cohorts of up to 18 mice using the IM technique. Athymic nude mice were selected for this purpose because of the ease of tumor detection and better tolerance of the chemotherapy. 17, 18 Once tumors reached a volume of 125 mm 3 , the mice were randomized to receive either matched patient chemotherapy [5-fluorouracil (5FU)/cisplatin] or the vehicle (0.9 % NaCl) alone. Cisplatin (DBL) was suspended in 0.9 % (w/ v) NaCl and administered at a dose of 4 mg/kg via intraperitoneal injection on a weekly basis for 3 weeks. 5FU (DBL) was suspended in 0.9 % NaCl and administered at 10 mg/kg via intraperitoneal injection on days 1 to 5 of a 14 day treatment cycle. This cycle was repeated twice. Given the rapid systemic absorption of both cisplatin and 5FU from the peritoneal cavity, the intraperitoneal route was chosen because of its ease of administration. 19, 20 
RESULTS
Tumor samples from 23 patients were harvested from the esophagus, gastroesophageal junction (GEJ), or peritoneum (metastatic deposit from a primary GEJ tumor). They included both adenocarcinoma and SCC. One to four tumor pieces (mode = 2) from each patient were implanted. Samples from four patients were lost because of the premature death of the host mice during the first month (i.e., before a tumor could become established) and were excluded from further analysis. Of the remaining patients, samples implanted using the IM technique had a per-implant success rate of 65 % (24/37) and resulted in successful engraftment of at least one implant from each of the 18 patients with this method (Table 1 ). In comparison, the SC technique had a per-implant success rate of only 9 % (1/11) and was associated with successful engraftment ofjust one of the six (16 %) patients (Table 1) .
All engrafted tissues were subjected to thorough histopathological analysis by an experienced histopathologist. All were demonstrated to be composed of human tissue, as demonstrated by staining with anti-human mitochondrial antibody (Fig. 1a) . Of the 18 engrafted lines, 13 were confirmed to be of epithelial origin and to have maintained the same degree of differentiation (Fig. 1a) and expression of molecular markers (Fig. 1b) as their parent tumor. Thus, we were able to establish bona fide esophageal PDTXs from 13 of 18 patients (72 %) using the IM technique compared to just one from six patients using the SC method.
Of the five IM xenografts that failed to recapitulate their parent tumors, four were confirmed to be B cell lymphomas, and one was composed of a combination of both epithelial and lymphoid cells (Fig. S2a) . These lymphomas stained strongly for Epstein-Barr virus (EBV) RNA (Fig.  S2d) , indicating that latent EBV may be the driver of this lymphomatous transformation. These five lymphoma lines were also reproducibly metastatic in the mice, with extranodal dissemination frequently noted in the lung, liver, and spleen (data not shown).
All of the validated esophageal PDTX lines have now been passaged up to seven times. We have also been able to reestablish four of the five esophageal PDTX lines following cryopreservation. All passages were performed in NSG mice except for the failed cryopreserved sample, which was implanted in NOD scid mice (Table 1) .
Targeted sequencing of 48 known cancer-related genes revealed the model to be relatively stable genetically. From a single PDTX line (patient 1), the original tumor was compared to seven PDTXs across three consecutive generations. Our results identified the presence of synonymous variants in five genes (FGFR3, PDGFRA, EGFR, RET, PTEN) and nonsynonymous variants in three genes (HNF1A, TP53, STK11) in the parent tumor. These were maintained in the original PDTX and subsequent passages, with the exception of one-second generation PDTX in which the STK11 variant was not detected.
Importantly, we confirmed that the therapeutic responses observed in the patients are reproducible within the PDTX. For example, patient 11, who had a poorly differentiated SCC of the mid to lower esophagus, experienced a complete response to a combination of chemotherapy (5FU and cisplatin) and radiotherapy (50.4 Gy over 28 fractions). This complete response was mirrored in the matching PDTX (Fig. 2a) . Similarly, patient 15, who underwent treatment for a moderately differentiated adenocarcinoma of the GEJ, demonstrated only a partial response to the combination of chemotherapy (5FU and cisplatin) and radiotherapy (50.4 Gy over 28 fractions), and this partial response was mirrored in the matching PDTX (Fig. 2b) .
DISCUSSION
We report a methodology for improved establishment of PDTXs from esophageal tumors. Using this novel IM technique, we were able to establish esophageal PDTX lines from 13 of 18 patients. These results suggest that this IM transplantation technique is more robust than the standard SC approach for generating esophageal PDTXs. Given our early success using the IM technique and the importance placed on generating additional PDTX lines from the limited quantity of tissue available, the majority of specimens in our series were implanted using the IM technique. Hence, the numbers were too low for a direct comparison of the ''take'' rate between the IM and SC techniques. Nevertheless, given that the best reported engraftment rate across a range of esophageal PDTX studies is only 38.5 %, 7-13 the IM technique appears to be superior. Caution is needed when making such a comparison, however, as the small numbers mean that it is not possible to standardize for variables such as ischemia time and tumor viability. We postulate that the improved ''take'' rate observed using the IM technique could possibly be attributed to the greater blood supply in the transplant bed. Evidence for this possibility can be extrapolated from a study of ectopic transplantation of ovarian tissue. 21 In that study, SC and IM transplantation sites were compared through a series of experiments involving xenografting normal rat ovarian tissue into nude mice. Results showed that the SC transplantation site exhibited pericyte loss and tissue damage, whereas the IM site maintained its vascularity and demonstrated tissue preservation. 21 It is also well established that there is greater autoregulatory control over blood flow in muscle tissue than in cutaneous tissue. 22 This control ensures that the temperature within the transplant bed remains relatively constant, protecting the tumor graft against hypothermic insult.
We confirmed that the esophageal PDTXs in our series are composed of human tissue and that they are representative of the original patient's tumor with respect to degree of differentiation and the molecular and genetic phenotypes. By assessing the response to standard chemotherapy, we have also produced evidence that the biology of the PDTX matches that of the original tumor. This finding highlights the potential power of wellvalidated PDTXs as preclinical tools for both biomarker validation and selection of second-line therapies.
The feasibility of cryopreserving esophageal PDTXs was also demonstrated in this study. This discovery has the potential to lead to significant reductions in the resources required to maintain perpetual PDTX biobanks. It also gives researchers the ability to share PDTX resources more readily with collaborators.
Researchers must also be cognizant of potential limitations when using PDTX models. Overall, 5 of the initial 18 established xenografts (26 %) underwent lymphomatous transformation. As it is not easy to distinguish poorly differentiated carcinomas from lymphomas by histology alone, it is important that poorly differentiated PDTXs are tested for the expression of lymphoma markers. Indeed, the process of lymphomatous transformation in xenografts has only recently been reported, 7, 23, 24 and it can be as high as 68 %, as reported in one series. 24 It is most likely that the lymphomas arise through transformation of EBV-infected B cells that have been transplanted with the tumor tissue piece into a permissive environment. The situation is akin to the development of lymphomas in immunodeficient patients, putatively modeling an EBV-driven posttransplant lymphoproliferative disorder. 25 Given the high rate of EBV infection in the general population, it seems likely that this phenomenon has either been under-recognized or underreported in the literature.
CONCLUSIONS
We have demonstrated that an IM transplant technique is associated with improved engraftment of esophageal PDTXs. Given the importance of the PDTX as a preclinical tool, it is hoped that this refinement will lead to greater understanding of cancer biology and improved therapies.
